Nuss John 4
4 · Ventyx Biosciences, Inc. · Filed Dec 19, 2025
Insider Transaction Report
Form 4
Nuss John
CHIEF SCIENTIFIC OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-12-17+34,930→ 502,156 total - Sale
Common Stock
2025-12-18$7.72/sh−12,675$97,840→ 489,481 total - Exercise/Conversion
Restricted Stock Units
2025-12-17−34,930→ 0 total→ Common Stock (34,930 underlying)
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Ventyx Biosciences, Inc. common stock.
- [F2]Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
- [F3]Represents the weighted average share price of an aggregate total of 12,675 shares sold in the price range of $7.595 to $7.85. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Subject to the reporting person's continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through such applicable vesting date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the RSUs subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean December 17, 2021.